Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-36.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.46 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -148.58% |
| Return on Assets (Trailing 12 Months) | -51.50% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.41 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.42 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.98 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.64 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.01 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.36 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 59.88M |
| Free Float | 52.52M |
| Market Capitalization | $173.06M |
| Average Volume (Last 20 Days) | 0.16M |
| Beta (Past 60 Months) | 0.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 56.77% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |